MN-DIGI-INTERNATIONAL
Digi International®, (NASDAQ: DGII), a leading provider of Internet of Things (IoT) connectivity solutions, today expanded its Digi XBee® 3 Global Cellular family of solutions with the unveiling of Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment. These new modules deliver the power and flexibility of the renowned Digi XBee ecosystem — pre-certified for global cellular deployments to accelerate development times and eliminate the costs associated with carrier certification processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005045/en/
Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment unveiled at Embedded World 2023. (Graphic: Business Wire)
The newest additions to the Digi XBee Global Cellular family are dependable, compact solutions with BLE and end-device carrier certifications that can be used worldwide and are equipped with Global Navigation Satellite System (GNSS) positioning. They deliver simplified and future-proof solutions for developers and original equipment manufacturers (OEMs) looking to add reliable cellular IoT connectivity to their devices or IoT gateways. With pre-integrated certifications, the XBee 3 Global family supports LTE Cat 1, LTE-M and NB-IoT networks, with 2G/3G fallback — for applications that require reliable cellular connectivity, anywhere in the world. These solutions support low-power applications such as meters, smart sensors and other fixed assets that send small portions of data.
Digi XBee Global Cellular family smart modems are designed to be provisioned, managed and monitored by Digi Remote Manager® (Digi RM). Additionally, they support MicroPython programming, Bluetooth, GNSS positioning for geolocation and Digi TrustFence® security.
“Our Digi XBee 3 Global Cellular family expands the XBee ecosystem of RF modules, gateways, adapters and software — giving OEMs access to the smallest, pre-certified modems for cellular networks that will save thousands in development time and money,” said Steve Ericson, Vice President and General Manager of Digi’s OEM Solutions division. “Pre-certification, along with the integration of advanced software and security, and a full ecosystem of tools supports rapid time-to-market.”
Digi XBee 3 Global Cellular Cat 1
Designed for applications that require higher throughput, the XBee 3 Cat 1 smart modem gives customers a single SKU for deployment of cellular products anywhere in the world. It includes 2G/3G fallback for use in regions and countries where Cat 1 isn’t available.
Digi XBee 3 Global Cellular LTE-M/NB-IoT
Offering low-power cellular connectivity, Digi XBee 3 LTE-M/NB-IoT modules are designed for applications that require data collection from edge devices — supporting higher data rates, lower latency and cell tower handoff, making it ideal for mobile applications and asset tracking.
Delivering the lowest power consumption and data transfer rates available, NB-IoT is ideal for battery-powered and passive devices, which transmit small amounts of data at intermittent times.
All smart modems within the XBee Cellular family solution include MicroPython programming resources to enable direct custom scripting, 2G/3G fallback to ensure connectivity, GNSS for accurate location services, OTA firmware updates and access to Digi Remote Manager for over-the-air software updates and monitoring. With built-in Digi TrustFence® security, identity and data privacy features, customers can tap into more than 175 controls to protect against new and evolving cyber threats. The Digi XBee Mobile App and Digi XBee Studio® tool suite simplify setup, configuration and testing. Digi XBee Data Plans are also available for a wide variety of cellular connectivity requirements.
Digi XBee 3 Global Cellular Family solutions are available now. For more information, visit: https://www.digi.com/products/embedded-systems/digi-xbee/cellular-modems.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom